Symbols / MIRA Stock $0.97 +1.85% MIRA Pharmaceuticals, Inc.
MIRA (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteMIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.
Ratings
Current target
$0.97
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-09-30 | init | Rodman & Renshaw | — → Buy | $17 |
| 2024-08-05 | init | Ascendiant Capital | — → Buy | $11 |
- MIRA Stock Chart | MIRA PHARMACEUTICALS INC (NASDAQ:MIRA) - ChartMill hu, 14 May 2026 07
- Mira Pharmaceuticals stock gains on Phase 1 trial results - Investing.com hu, 14 May 2026 12
- MIRA Pharmaceuticals (MIRA) posts Q1 2026 loss and warns on going concern - Stock Titan hu, 14 May 2026 19
- Mira Pharmaceuticals Stock Soars 70% After-Hours As Pain Drug Outperforms Morphine; Retail Sees ‘Blockbuster Drug’ In The Making - Stocktwits hu, 05 Mar 2026 08
- MIRA highlights SKNY-1 preclinical data in new publication - TipRanks Wed, 13 May 2026 12
- MIRA Pharmaceuticals Inc. (MIRA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade hu, 16 Oct 2025 14
- Fish study: MIRA test pill cuts weight 30% and dampens nicotine-seeking - Stock Titan Wed, 13 May 2026 12
- Mira Pharmaceuticals stock gains on Phase 1 trial results By Investing.com - Investing.com South Africa hu, 14 May 2026 13
- Chemo nerve damage has no FDA drugs—MIRA advances new Ketamir-2 pill - Stock Titan hu, 14 May 2026 12
- Mira Pharmaceuticals increases at-the-market offering by $15.2 million - Investing.com Fri, 05 Dec 2025 08
- MIRA tests oral Ketamir-2 for chemo nerve pain after safe Phase 1 - Stock Titan Wed, 04 Mar 2026 08
- MIRA Pharmaceuticals reports phase 1 results for Ketamir-2 By Investing.com - Investing.com Nigeria hu, 14 May 2026 12
- MIRA pain drug showed morphine-like relief without THC-like effects - Stock Titan Mon, 23 Mar 2026 07
- MIRA Pharmaceuticals (MIRA) CEO granted 83,500 RSUs - Stock Titan Wed, 01 Apr 2026 07
- MIRA Pharmaceuticals (NASDAQ: MIRA) highlights SKNY-1 preclinical obesity and nicotine data - Stock Titan Wed, 13 May 2026 11
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
10.49
+30.86%
|
8.02
-5.95%
|
8.53
+20.97%
|
7.05
|
| Research And Development |
|
1.72
-47.97%
|
3.31
+110.15%
|
1.57
-33.11%
|
2.35
|
| Selling General And Administration |
|
8.77
+86.16%
|
4.71
-27.49%
|
6.50
+117.22%
|
2.99
|
| General And Administrative Expense |
|
8.77
+86.16%
|
4.71
-27.49%
|
6.50
+117.22%
|
2.99
|
| Other Gand A |
|
8.77
+86.16%
|
4.71
-27.49%
|
6.50
+117.22%
|
2.99
|
| Other Operating Expenses |
|
—
|
—
|
0.45
-73.39%
|
1.70
|
| Total Expenses |
|
10.49
+30.86%
|
8.02
-5.95%
|
8.53
+20.97%
|
7.05
|
| Operating Income |
|
-10.49
-30.86%
|
-8.02
+5.95%
|
-8.53
-20.97%
|
-7.05
|
| EBITDA |
|
-10.49
-30.86%
|
-8.02
+5.95%
|
-8.53
-20.97%
|
-7.05
|
| Normalized EBITDA |
|
-10.46
-30.42%
|
-8.02
+5.95%
|
-8.53
-20.97%
|
-7.05
|
| EBIT |
|
-10.49
-30.86%
|
-8.02
+5.95%
|
-8.53
-20.97%
|
-7.05
|
| Total Unusual Items |
|
-0.04
|
—
|
—
|
—
|
| Total Unusual Items Excluding Goodwill |
|
-0.04
|
—
|
—
|
—
|
| Net Income |
|
-10.44
-32.98%
|
-7.85
+34.46%
|
-11.98
-69.77%
|
-7.06
|
| Pretax Income |
|
-10.44
-32.98%
|
-7.85
+34.46%
|
-11.98
-69.77%
|
-7.06
|
| Net Non Operating Interest Income Expense |
|
0.10
-40.30%
|
0.17
+104.79%
|
-3.46
-33619.94%
|
-0.01
|
| Interest Expense Non Operating |
|
—
|
—
|
3.46
+33619.94%
|
0.01
|
| Net Interest Income |
|
0.10
-40.30%
|
0.17
+104.79%
|
-3.46
-33619.94%
|
-0.01
|
| Interest Expense |
|
—
|
—
|
3.46
+33619.94%
|
0.01
|
| Interest Income Non Operating |
|
0.10
-40.30%
|
0.17
|
—
|
—
|
| Interest Income |
|
0.10
-40.30%
|
0.17
|
—
|
—
|
| Other Income Expense |
|
-0.05
|
—
|
—
|
—
|
| Other Non Operating Income Expenses |
|
-0.01
|
—
|
—
|
—
|
| Gain On Sale Of Security |
|
-0.04
|
—
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-10.44
-32.98%
|
-7.85
+34.46%
|
-11.98
-69.77%
|
-7.06
|
| Net Income From Continuing Operation Net Minority Interest |
|
-10.44
-32.98%
|
-7.85
+34.46%
|
-11.98
-69.77%
|
-7.06
|
| Net Income From Continuing And Discontinued Operation |
|
-10.44
-32.98%
|
-7.85
+34.46%
|
-11.98
-69.77%
|
-7.06
|
| Net Income Continuous Operations |
|
-10.44
-32.98%
|
-7.85
+34.46%
|
-11.98
-69.77%
|
-7.06
|
| Normalized Income |
|
-10.41
-32.53%
|
-7.85
+34.46%
|
-11.98
-69.77%
|
-7.06
|
| Net Income Common Stockholders |
|
-32.00
-307.50%
|
-7.85
+34.46%
|
-11.98
-69.77%
|
-7.06
|
| Otherunder Preferred Stock Dividend |
|
21.56
|
0.00
|
—
|
—
|
| Diluted EPS |
|
-1.35
-164.71%
|
-0.51
+40.00%
|
-0.85
-113.77%
|
-0.40
|
| Basic EPS |
|
-1.35
-164.71%
|
-0.51
+40.00%
|
-0.85
-113.77%
|
-0.40
|
| Basic Average Shares |
|
23.69
+53.42%
|
15.44
+10.91%
|
13.92
-21.55%
|
17.75
|
| Diluted Average Shares |
|
23.69
+53.42%
|
15.44
+10.91%
|
13.92
-21.55%
|
17.75
|
| Diluted NI Availto Com Stockholders |
|
-32.00
-307.50%
|
-7.85
+34.46%
|
-11.98
-69.77%
|
-7.06
|
| Total Other Finance Cost |
|
—
|
-0.17
-104.79%
|
3.46
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
11.09
+279.52%
|
2.92
-40.74%
|
4.93
+474.83%
|
0.86
|
| Current Assets |
|
11.06
+282.95%
|
2.89
-40.56%
|
4.86
+882.64%
|
0.49
|
| Cash Cash Equivalents And Short Term Investments |
|
11.03
+289.35%
|
2.83
-38.45%
|
4.60
+1211.35%
|
0.35
|
| Cash And Cash Equivalents |
|
6.35
+124.04%
|
2.83
-38.45%
|
4.60
+1211.35%
|
0.35
|
| Cash Financial |
|
6.35
+124.04%
|
2.83
-38.45%
|
4.60
+1211.35%
|
0.35
|
| Other Short Term Investments |
|
4.68
|
0.00
|
—
|
—
|
| Receivables |
|
—
|
0.00
-100.00%
|
0.01
|
0.00
|
| Other Receivables |
|
—
|
—
|
0.01
|
—
|
| Prepaid Assets |
|
0.03
-48.57%
|
0.05
-77.55%
|
0.24
|
0.00
|
| Current Deferred Assets |
|
—
|
—
|
0.00
-100.00%
|
0.14
|
| Total Non Current Assets |
|
0.04
+0.00%
|
0.04
-52.25%
|
0.07
-79.59%
|
0.36
|
| Net PPE |
|
—
|
0.00
-100.00%
|
0.01
-98.61%
|
0.36
|
| Gross PPE |
|
—
|
0.00
-100.00%
|
0.01
-98.61%
|
0.36
|
| Other Properties |
|
—
|
—
|
0.01
-98.61%
|
0.36
|
| Non Current Accounts Receivable |
|
0.04
+0.00%
|
0.04
-48.75%
|
0.07
|
—
|
| Non Current Prepaid Assets |
|
—
|
—
|
—
|
0.00
|
| Total Liabilities Net Minority Interest |
|
0.70
-2.94%
|
0.72
+29.61%
|
0.56
-61.62%
|
1.45
|
| Current Liabilities |
|
0.70
-2.94%
|
0.72
+29.61%
|
0.56
-59.26%
|
1.37
|
| Payables And Accrued Expenses |
|
0.70
-2.94%
|
0.72
+30.80%
|
0.55
-42.58%
|
0.96
|
| Payables |
|
0.70
-2.94%
|
0.72
+34.31%
|
0.54
-40.53%
|
0.91
|
| Accounts Payable |
|
0.13
-82.14%
|
0.72
+34.31%
|
0.54
-31.76%
|
0.79
|
| Current Accrued Expenses |
|
—
|
0.00
-100.00%
|
0.01
-74.84%
|
0.06
|
| Current Debt And Capital Lease Obligation |
|
—
|
—
|
0.01
-98.76%
|
0.41
|
| Current Debt |
|
—
|
—
|
—
|
0.13
|
| Current Capital Lease Obligation |
|
—
|
0.00
-100.00%
|
0.01
-98.15%
|
0.27
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.08
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
—
|
0.00
-100.00%
|
0.08
|
| Long Term Capital Lease Obligation |
|
—
|
—
|
0.00
-100.00%
|
0.08
|
| Stockholders Equity |
|
10.39
+372.40%
|
2.20
-49.71%
|
4.37
+833.67%
|
-0.60
|
| Common Stock Equity |
|
10.39
+372.40%
|
2.20
-49.71%
|
4.37
+833.67%
|
-0.60
|
| Capital Stock |
|
0.00
+153.26%
|
0.00
+12.04%
|
0.00
-77.80%
|
0.01
|
| Common Stock |
|
0.00
+153.26%
|
0.00
+12.04%
|
0.00
-77.80%
|
0.01
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
41.94
+153.24%
|
16.56
+12.04%
|
14.78
+0.24%
|
14.75
|
| Ordinary Shares Number |
|
41.94
+153.24%
|
16.56
+12.04%
|
14.78
+0.24%
|
14.75
|
| Additional Paid In Capital |
|
49.97
+59.46%
|
31.34
+22.13%
|
25.66
+194.92%
|
8.70
|
| Retained Earnings |
|
-39.58
-35.84%
|
-29.14
-36.89%
|
-21.29
-128.80%
|
-9.30
|
| Total Equity Gross Minority Interest |
|
10.39
+372.40%
|
2.20
-49.71%
|
4.37
+833.67%
|
-0.60
|
| Total Capitalization |
|
10.39
+372.40%
|
2.20
-49.71%
|
4.37
+833.67%
|
-0.60
|
| Working Capital |
|
10.36
+378.49%
|
2.16
-49.67%
|
4.30
+591.09%
|
-0.88
|
| Invested Capital |
|
10.39
+372.40%
|
2.20
-49.71%
|
4.37
+1044.44%
|
-0.46
|
| Total Debt |
|
—
|
0.00
-100.00%
|
0.01
-98.97%
|
0.49
|
| Capital Lease Obligations |
|
—
|
0.00
-100.00%
|
0.01
-98.59%
|
0.36
|
| Net Tangible Assets |
|
10.39
+372.40%
|
2.20
-49.71%
|
4.37
+833.67%
|
-0.60
|
| Tangible Book Value |
|
10.39
+372.40%
|
2.20
-49.71%
|
4.37
+833.67%
|
-0.60
|
| Duefrom Related Parties Non Current |
|
0.04
+0.00%
|
0.04
-48.75%
|
0.07
|
0.00
|
| Dueto Related Parties Current |
|
0.57
|
0.00
|
0.00
-100.00%
|
0.12
|
| Interest Payable |
|
—
|
0.00
-100.00%
|
0.01
-58.64%
|
0.03
|
| Line Of Credit |
|
—
|
—
|
0.00
-100.00%
|
0.13
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-4.66
+16.17%
|
-5.56
-22.69%
|
-4.53
+19.13%
|
-5.60
|
| Cash Flow From Continuing Operating Activities |
|
-4.66
+16.17%
|
-5.56
-22.69%
|
-4.53
+19.13%
|
-5.60
|
| Net Income From Continuing Operations |
|
-10.44
-32.98%
|
-7.85
+34.46%
|
-11.98
-69.77%
|
-7.06
|
| Other Non Cash Items |
|
—
|
—
|
5.54
+53935.92%
|
0.01
|
| Stock Based Compensation |
|
6.31
+228.67%
|
1.92
-24.70%
|
2.55
+96.74%
|
1.30
|
| Unrealized Gain Loss On Investment Securities |
|
0.04
|
0.00
|
—
|
—
|
| Change In Working Capital |
|
-0.57
-252.88%
|
0.37
+158.04%
|
-0.64
-536.41%
|
0.15
|
| Change In Receivables |
|
0.00
-100.00%
|
0.01
+200.00%
|
-0.01
|
0.00
|
| Changes In Account Receivables |
|
—
|
0.01
+200.00%
|
-0.01
|
0.00
|
| Change In Prepaid Assets |
|
0.03
-85.94%
|
0.19
+177.55%
|
-0.24
|
0.00
|
| Change In Payables And Accrued Expense |
|
-0.59
-448.86%
|
0.17
+143.72%
|
-0.39
-356.13%
|
0.15
|
| Change In Accrued Expense |
|
0.00
+100.00%
|
-0.01
|
0.00
|
—
|
| Change In Payable |
|
-0.59
-421.53%
|
0.18
+147.44%
|
-0.39
|
—
|
| Change In Account Payable |
|
-0.59
-421.53%
|
0.18
+147.44%
|
-0.39
|
—
|
| Change In Other Current Assets |
|
—
|
0.00
-100.00%
|
0.01
+200.00%
|
-0.01
|
| Change In Other Current Liabilities |
|
—
|
—
|
1.10
|
0.00
|
| Financing Cash Flow |
|
8.18
+115.66%
|
3.79
-56.84%
|
8.78
+179.19%
|
3.15
|
| Cash Flow From Continuing Financing Activities |
|
8.18
+115.66%
|
3.79
-56.84%
|
8.78
+179.19%
|
3.15
|
| Net Issuance Payments Of Debt |
|
0.57
|
0.00
-100.00%
|
1.01
+728.40%
|
-0.16
|
| Issuance Of Debt |
|
0.57
|
0.00
-100.00%
|
2.15
|
0.00
|
| Repayment Of Debt |
|
—
|
0.00
+100.00%
|
-1.14
-614.05%
|
-0.16
|
| Long Term Debt Issuance |
|
0.57
|
0.00
|
—
|
—
|
| Net Long Term Debt Issuance |
|
0.57
|
0.00
|
—
|
—
|
| Short Term Debt Issuance |
|
—
|
0.00
-100.00%
|
2.15
|
0.00
|
| Short Term Debt Payments |
|
—
|
0.00
+100.00%
|
-1.14
-614.05%
|
-0.16
|
| Net Short Term Debt Issuance |
|
—
|
0.00
-100.00%
|
1.01
+728.40%
|
-0.16
|
| Net Common Stock Issuance |
|
7.01
+94.18%
|
3.61
-53.16%
|
7.70
+165.30%
|
2.90
|
| Proceeds From Stock Option Exercised |
|
0.89
|
0.00
|
—
|
—
|
| Net Other Financing Charges |
|
-0.29
-260.33%
|
0.18
+145.60%
|
0.07
-81.53%
|
0.40
|
| Changes In Cash |
|
3.51
+298.57%
|
-1.77
-141.62%
|
4.25
+272.93%
|
-2.46
|
| Beginning Cash Position |
|
2.83
-38.45%
|
4.60
+1211.35%
|
0.35
-87.51%
|
2.81
|
| End Cash Position |
|
6.35
+124.04%
|
2.83
-38.45%
|
4.60
+1211.35%
|
0.35
|
| Free Cash Flow |
|
-4.66
+16.17%
|
-5.56
-22.69%
|
-4.53
+19.13%
|
-5.60
|
| Interest Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
—
|
| Change In Interest Payable |
|
0.00
+100.00%
|
-0.01
|
0.00
|
—
|
| Common Stock Issuance |
|
7.01
+94.18%
|
3.61
-53.16%
|
7.70
+165.30%
|
2.90
|
| Issuance Of Capital Stock |
|
7.01
+94.18%
|
3.61
-53.16%
|
7.70
+165.30%
|
2.90
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-Q2026-05-14 View
- 8-K2026-05-13 View
- 8-K2026-05-13 View
- 42026-04-01 View
- 10-K2026-03-31 View
- 8-K2026-03-23 View
- 8-K2026-03-03 View
- 8-K2026-02-02 View
- 8-K2025-12-22 View
- 8-K2025-12-05 View
- 10-Q2025-11-13 View
- 8-K2025-10-23 View
- 8-K2025-10-16 View
- 8-K2025-10-15 View
- 42025-10-03 View
- 42025-10-03 View
- 8-K2025-09-30 View
- 8-K2025-09-22 View
- 42025-09-18 View
- 8-K2025-09-15 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|